事実根拠 1
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
PR Newswire news releases · 2026-10-07 19:08
証拠を見る
- 企業開示PR Newswire news releases2026-10-07 19:08
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
出典を見る